First Time Loading...

Krystal Biotech Inc
NASDAQ:KRYS

Watchlist Manager
Krystal Biotech Inc Logo
Krystal Biotech Inc
NASDAQ:KRYS
Watchlist
Price: 163.97 USD -3.34% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. [ Read More ]

The intrinsic value of one KRYS stock under the Base Case scenario is 123.92 USD. Compared to the current market price of 163.97 USD, Krystal Biotech Inc is Overvalued by 24%.

Key Points:
KRYS Intrinsic Value
Base Case
123.92 USD
Overvaluation 24%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Krystal Biotech Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KRYS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Krystal Biotech Inc

Provide an overview of the primary business activities
of Krystal Biotech Inc.

What unique competitive advantages
does Krystal Biotech Inc hold over its rivals?

What risks and challenges
does Krystal Biotech Inc face in the near future?

Has there been any significant insider trading activity
in Krystal Biotech Inc recently?

Summarize the latest earnings call
of Krystal Biotech Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Krystal Biotech Inc.

Provide P/S
for Krystal Biotech Inc.

Provide P/E
for Krystal Biotech Inc.

Provide P/OCF
for Krystal Biotech Inc.

Provide P/FCFE
for Krystal Biotech Inc.

Provide P/B
for Krystal Biotech Inc.

Provide EV/S
for Krystal Biotech Inc.

Provide EV/GP
for Krystal Biotech Inc.

Provide EV/EBITDA
for Krystal Biotech Inc.

Provide EV/EBIT
for Krystal Biotech Inc.

Provide EV/OCF
for Krystal Biotech Inc.

Provide EV/FCFF
for Krystal Biotech Inc.

Provide EV/IC
for Krystal Biotech Inc.

Show me price targets
for Krystal Biotech Inc made by professional analysts.

What are the Revenue projections
for Krystal Biotech Inc?

How accurate were the past Revenue estimates
for Krystal Biotech Inc?

What are the Net Income projections
for Krystal Biotech Inc?

How accurate were the past Net Income estimates
for Krystal Biotech Inc?

What are the EPS projections
for Krystal Biotech Inc?

How accurate were the past EPS estimates
for Krystal Biotech Inc?

What are the EBIT projections
for Krystal Biotech Inc?

How accurate were the past EBIT estimates
for Krystal Biotech Inc?

Compare the revenue forecasts
for Krystal Biotech Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Krystal Biotech Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Krystal Biotech Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Krystal Biotech Inc compared to its peers.

Compare the P/E ratios
of Krystal Biotech Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Krystal Biotech Inc with its peers.

Analyze the financial leverage
of Krystal Biotech Inc compared to its main competitors.

Show all profitability ratios
for Krystal Biotech Inc.

Provide ROE
for Krystal Biotech Inc.

Provide ROA
for Krystal Biotech Inc.

Provide ROIC
for Krystal Biotech Inc.

Provide ROCE
for Krystal Biotech Inc.

Provide Gross Margin
for Krystal Biotech Inc.

Provide Operating Margin
for Krystal Biotech Inc.

Provide Net Margin
for Krystal Biotech Inc.

Provide FCF Margin
for Krystal Biotech Inc.

Show all solvency ratios
for Krystal Biotech Inc.

Provide D/E Ratio
for Krystal Biotech Inc.

Provide D/A Ratio
for Krystal Biotech Inc.

Provide Interest Coverage Ratio
for Krystal Biotech Inc.

Provide Altman Z-Score Ratio
for Krystal Biotech Inc.

Provide Quick Ratio
for Krystal Biotech Inc.

Provide Current Ratio
for Krystal Biotech Inc.

Provide Cash Ratio
for Krystal Biotech Inc.

What is the historical Revenue growth
over the last 5 years for Krystal Biotech Inc?

What is the historical Net Income growth
over the last 5 years for Krystal Biotech Inc?

What is the current Free Cash Flow
of Krystal Biotech Inc?

Financials

Balance Sheet Decomposition
Krystal Biotech Inc

Current Assets 587.9m
Cash & Short-Term Investments 532.2m
Receivables 42m
Other Current Assets 13.7m
Non-Current Assets 230.4m
Long-Term Investments 62m
PP&E 168.2m
Other Non-Current Assets 263k
Current Liabilities 33.1m
Accounts Payable 4.1m
Accrued Liabilities 24.5m
Other Current Liabilities 4.5m
Non-Current Liabilities 6.6m
Other Non-Current Liabilities 6.6m
Efficiency

Earnings Waterfall
Krystal Biotech Inc

Revenue
50.7m USD
Cost of Revenue
-3.1m USD
Gross Profit
47.6m USD
Operating Expenses
-144.8m USD
Operating Income
-97.2m USD
Other Expenses
108.2m USD
Net Income
10.9m USD

Free Cash Flow Analysis
Krystal Biotech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

KRYS Profitability Score
Profitability Due Diligence

Krystal Biotech Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
ROE is Increasing
Positive Gross Profit
30/100
Profitability
Score

Krystal Biotech Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

KRYS Solvency Score
Solvency Due Diligence

Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KRYS Price Targets Summary
Krystal Biotech Inc

Wall Street analysts forecast KRYS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KRYS is 192.27 USD with a low forecast of 154.53 USD and a high forecast of 218.4 USD.

Lowest
Price Target
154.53 USD
6% Downside
Average
Price Target
192.27 USD
17% Upside
Highest
Price Target
218.4 USD
33% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KRYS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KRYS Price
Krystal Biotech Inc

1M 1M
-2%
6M 6M
+49%
1Y 1Y
+84%
3Y 3Y
+119%
5Y 5Y
+407%
10Y 10Y
+1 441%
Annual Price Range
163.97
52w Low
82.18
52w High
180.42
Price Metrics
Average Annual Return 27.96%
Standard Deviation of Annual Returns 33.03%
Max Drawdown -25%
Shares Statistics
Market Capitalization 4.6B USD
Shares Outstanding 28 514 500
Percentage of Shares Shorted 10.08%

KRYS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Krystal Biotech Inc Logo
Krystal Biotech Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.6B USD

Dividend Yield

0%

Description

Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 119 full-time employees. The company went IPO on 2017-09-20. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The firm's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.

Contact

PENNSYLVANIA
Pittsburgh
2100 Wharton St Ste 701
+14125865830.0
https://www.krystalbio.com/

IPO

2017-09-20

Employees

119

Officers

Founder, Chairman, President & CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Founder, COO, President of R&D and Director
Ms. Suma M. Krishnan
Executive VP & Chief Accounting Officer
Ms. Kathryn A. Romano
General Counsel & Corporate Secretary
Mr. John Thomas
Vice President of North American Sales & Marketing
Mr. John Karakkal
Head of U.S. Sales and Marketing
Ms. Christine Wilson
Show More
Director of Human Resources & Operations
Mr. Josh Suskin
Senior Vice President of Clinical Development
Dr. Hubert C. Chen M.D.
Senior VP & GM of Europe
Mr. Laurent Goux
Senior Vice President of CMC & Technical Operations
Mr. Ram Kamineni
Show Less

See Also

Discover More
What is the Intrinsic Value of one KRYS stock?

The intrinsic value of one KRYS stock under the Base Case scenario is 123.92 USD.

Is KRYS stock undervalued or overvalued?

Compared to the current market price of 163.97 USD, Krystal Biotech Inc is Overvalued by 24%.